12 Month Price Forecast For EVH
Distance to EVH Price Forecasts
EVH Price Momentum
๐ค Considering Evolent Health (EVH)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 15, 2025 2:17 PM UTC
EVH Analyst Ratings & Price Targets
Based on our analysis of 24 Wall Street analysts, EVH has a bullish consensus with a median price target of $15.00 (ranging from $12.00 to $47.21). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $10.02, the median forecast implies a 49.7% upside. This outlook is supported by 15 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Constantine Davides at JMP Securities, suggesting a 19.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EVH Analyst Consensus
EVH Price Target Range
Latest EVH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EVH.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Feb 14, 2025 | JMP Securities | Constantine Davides | Market Outperform | Reiterates | $12.00 |
Feb 12, 2025 | Needham | Ryan MacDonald | Buy | Reiterates | $15.00 |
Jan 28, 2025 | JP Morgan | Anne Samuel | Overweight | Maintains | $13.00 |
Jan 24, 2025 | Oppenheimer | Jeff Jones | Outperform | Maintains | $18.00 |
Jan 23, 2025 | Canaccord Genuity | Richard Close | Buy | Maintains | $16.00 |
Jan 22, 2025 | Truist Securities | Jailendra Singh | Buy | Maintains | $15.00 |
Jan 21, 2025 | Stephens & Co. | Jeff Garro | Equal-Weight | Maintains | $12.00 |
Jan 16, 2025 | UBS | Kevin Caliendo | Buy | Maintains | $14.00 |
Jan 15, 2025 | Needham | Ryan MacDonald | Buy | Reiterates | $15.00 |
Jan 14, 2025 | RBC Capital | Sean Dodge | Outperform | Maintains | $17.00 |
Jan 13, 2025 | Truist Securities | Jailendra Singh | Buy | Maintains | $20.00 |
Jan 10, 2025 | Needham | Matthew Sheerin | Buy | Initiates | $15.00 |
Jan 10, 2025 | JMP Securities | Constantine Davides | Market Outperform | Maintains | $18.00 |
Jan 10, 2025 | Citigroup | Daniel Grosslight | Buy | Maintains | $18.00 |
Nov 22, 2024 | JP Morgan | Anne Samuel | Overweight | Maintains | $15.00 |
Nov 18, 2024 | Oppenheimer | Jeff Jones | Outperform | Maintains | $28.00 |
Nov 13, 2024 | Citigroup | Daniel Grosslight | Buy | Maintains | $21.00 |
Nov 12, 2024 | RBC Capital | Sean Dodge | Outperform | Reiterates | $20.00 |
Nov 11, 2024 | Barclays | Stephanie Davis | Overweight | Maintains | $19.00 |
Nov 8, 2024 | Oppenheimer | Jeff Jones | Outperform | Maintains | $34.00 |
Stocks Similar to Evolent Health Inc
The following stocks are similar to Evolent Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Evolent Health Inc (EVH) Financial Data
Evolent Health Inc has a market capitalization of $1.15B with a P/E ratio of -7.8x. The company generates $2.46B in trailing twelve-month revenue with a -2.9% profit margin.
Revenue growth is +21.6% quarter-over-quarter, while maintaining an operating margin of -2.6% and return on equity of -5.8%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Evolent Health Inc (EVH) Company Overview
About Evolent Health Inc
Provides specialty care management services.
The company operates a business model that focuses on specialty care management across oncology, cardiology, and musculoskeletal markets. It generates revenue by offering a range of services including health plan administration, pharmacy benefits management, risk management, and analytics, as well as its proprietary technology platform, Identifi, which enhances care workflows and patient engagement.
Founded in 2011 and headquartered in Arlington, Virginia, Evolent Health, Inc. positions itself in the growing market of value-based healthcare, aiming to optimize total cost of care management for health plans and providers.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
4,700
CEO
Mr. Seth Barrie Blackley
Country
United States
IPO Year
2015
Website
www.evolent.comEvolent Health Inc (EVH) Latest News & Analysis
Evolent Health will appoint Rick Jelinek as Chair of the Board at the 2025 Annual Meeting, continuing its board refreshment with Brendan Springstubb as a new independent director.
Leadership changes can signal strategic shifts and impact corporate governance, influencing investor confidence and stock performance. Board refreshment may enhance decision-making and shareholder relations.
New Strong Sell Stocks for January 30th
16 days agoDEC, ERO, and EVH have been assigned a Zacks Rank #5 (Strong Sell) as of January 30, 2024. Investors may want to assess their holdings in these stocks.
Zacks Rank #5 indicates a significant downgrade for DEC, ERO, and EVH, signaling potential underperformance, which can lead to declining stock prices and investor losses.
Evolent Health, Inc. (NYSE: EVH) will release Q4 2024 financial results on February 20, 2025, after market close, followed by a conference call at 5 p.m. ET. Details available on their investor relations site.
Evolent Health's upcoming financial results and conference call may influence stock performance, offering insights into its financial health and operational progress, crucial for investment decisions.
Evolent Health has appointed Dr. Von Nguyen as Chief Medical Officer, effective January 1, 2025. Dr. Andrew Hertler will serve as senior advisor and CMO emeritus.
Leadership changes can signal strategic shifts within a company. Dr. Nguyen's appointment may influence Evolent Health's direction and performance, impacting investor sentiment and stock valuation.
New Strong Sell Stocks for December 12th
2 months agoASH, BIDU, and EVH have been assigned a Zacks Rank #5 (Strong Sell) as of December 12, 2024.
ASH, BIDU, and EVH being added to a Strong Sell list signals potential underperformance, prompting investors to reassess their holdings and strategy for these stocks.
Evolent Health's stock dropped 50% after a Q3 earnings miss and high costs, but it secured record deals and expects 15% annual revenue growth. The P/E ratio stands at 16.57, indicating potential value.
Evolent Health's significant stock drop reflects short-term setbacks, yet strong new business and growth projections indicate potential recovery, making it a contrarian buy with an attractive valuation.
Frequently Asked Questions About EVH Stock
What is Evolent Health Inc's (EVH) stock forecast for 2025?
Based on our analysis of 24 Wall Street analysts, Evolent Health Inc (EVH) has a median price target of $15.00. The highest price target is $47.21 and the lowest is $12.00.
Is EVH stock a good investment in 2025?
According to current analyst ratings, EVH has 15 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $10.02. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for EVH stock?
Wall Street analysts predict EVH stock could reach $15.00 in the next 12 months. This represents a 49.7% increase from the current price of $10.02. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Evolent Health Inc's business model?
The company operates a business model that focuses on specialty care management across oncology, cardiology, and musculoskeletal markets. It generates revenue by offering a range of services including health plan administration, pharmacy benefits management, risk management, and analytics, as well as its proprietary technology platform, Identifi, which enhances care workflows and patient engagement.
What is the highest forecasted price for EVH Evolent Health Inc?
The highest price target for EVH is $47.21 from at , which represents a 371.2% increase from the current price of $10.02.
What is the lowest forecasted price for EVH Evolent Health Inc?
The lowest price target for EVH is $12.00 from Constantine Davides at JMP Securities, which represents a 19.8% increase from the current price of $10.02.
What is the overall EVH consensus from analysts for Evolent Health Inc?
The overall analyst consensus for EVH is bullish. Out of 24 Wall Street analysts, 15 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $15.00.
How accurate are EVH stock price projections?
Stock price projections, including those for Evolent Health Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.